MA52300A - Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer - Google Patents

Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer

Info

Publication number
MA52300A
MA52300A MA052300A MA52300A MA52300A MA 52300 A MA52300 A MA 52300A MA 052300 A MA052300 A MA 052300A MA 52300 A MA52300 A MA 52300A MA 52300 A MA52300 A MA 52300A
Authority
MA
Morocco
Prior art keywords
neoplasics
platinum
cancer
agents
treatment
Prior art date
Application number
MA052300A
Other languages
English (en)
French (fr)
Inventor
Folgueira Judit Anido
Patricia Anne Giblin
Robin Matthew Hallett
Jeanne Magram
Naimish Pandya
Suarez Joan Seoane
Angus Sinclair
Robert Wasserman
Original Assignee
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Inst Catalana Recerca Estudis Avancats
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron, Inst Catalana Recerca Estudis Avancats, Medimmune Ltd filed Critical Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Publication of MA52300A publication Critical patent/MA52300A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052300A 2018-06-18 2019-06-17 Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer MA52300A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382432 2018-06-18

Publications (1)

Publication Number Publication Date
MA52300A true MA52300A (fr) 2021-04-21

Family

ID=62837845

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052300A MA52300A (fr) 2018-06-18 2019-06-17 Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer

Country Status (12)

Country Link
US (1) US20210187106A1 (enExample)
EP (1) EP3806899A2 (enExample)
JP (2) JP7379390B2 (enExample)
KR (1) KR20210022065A (enExample)
CN (1) CN112955178B (enExample)
AU (2) AU2019291307B2 (enExample)
CA (1) CA3103369A1 (enExample)
EA (1) EA202092964A1 (enExample)
IL (1) IL279444A (enExample)
MA (1) MA52300A (enExample)
SG (1) SG11202012576QA (enExample)
WO (1) WO2019243900A2 (enExample)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
CA2958685A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies
EP3283886B1 (en) * 2015-04-17 2020-01-15 Eisai Inc. Methods for treating lung cancer
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
KR20210008514A (ko) * 2018-05-14 2021-01-22 메디뮨 리미티드 Lif에 대한 항체 및 이의 투여 형태

Also Published As

Publication number Publication date
AU2024204564A1 (en) 2024-07-18
KR20210022065A (ko) 2021-03-02
AU2019291307A1 (en) 2021-02-04
WO2019243900A2 (en) 2019-12-26
EP3806899A2 (en) 2021-04-21
AU2019291307B2 (en) 2024-04-04
JP2024023212A (ja) 2024-02-21
JP2021533084A (ja) 2021-12-02
JP7603772B2 (ja) 2024-12-20
CA3103369A1 (en) 2019-12-26
IL279444A (en) 2021-01-31
WO2019243900A3 (en) 2020-03-05
CN112955178A (zh) 2021-06-11
EA202092964A1 (ru) 2021-03-30
US20210187106A1 (en) 2021-06-24
SG11202012576QA (en) 2021-01-28
CN112955178B (zh) 2025-03-11
JP7379390B2 (ja) 2023-11-14

Similar Documents

Publication Publication Date Title
IL282487A (en) Tyk2 inhibitors and uses thereof
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
HUE058931T2 (hu) Pilokarpin hidroklorid alkalmazása presbyopia kezelésére
EP3908270A4 (en) COMBINATION OF DEXTROMETHORPHANE AND BUPROPION FOR THE TREATMENT OF DEPRESSION
EP3796920A4 (en) TRNA/PRE-MIRNA COMPOSITIONS AND USE IN THE TREATMENT OF CANCER
EP3377042A4 (en) MATERIALS AND METHOD FOR THE TREATMENT OF TITIN-BASED MYOPATHIES AND OTHER TITINOPATHIES
IL286248A (en) Tyk2 inhibitors and uses thereof
MA71474A (fr) Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine
JOP20210324A1 (ar) مشتقات من 2h-indazole واستخدامها في علاج مرض
EP3653630A4 (en) ENDOCYCLIC THIAMIDINOAMIDE-ARYLAMIDE COMPOUND AND USE THEREOF FOR TREATMENT OF HEPATITIS B.
MA54290A (fr) Inhibiteur de kinase aurora a destiné à être utilisé dans le traitement du neuroblastome
EP3749344A4 (en) METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
MA55965A (fr) Combinaison d'inhibiteurs pd-1 et d'inhibiteurs lag-3 pour une efficacité améliorée dans le traitement du cancer
PL3972643T3 (pl) Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych
IL283899A (en) Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
SI3947375T1 (sl) Imidazolonilkinolinske spojine in terapevtske uporabe le-teh
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
EP3937980A4 (en) Modified micrornas and their use in the treatment of cancer
IL277404A (en) C3-binding substances and methods of using them
IL287043A (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
EP3813870C0 (en) CCR5 INHIBITOR FOR USE IN THE TREATMENT OF CANCER
MA52231A (fr) Combinaison d'inhibiteurs de lif et d'inhibiteurs de l'axe pd-1 pour une utilisation dans le traitement du cancer
IL289758A (en) Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries